19p Deletion in recurring leiomyosarcoma lesions from the same patient

Paola Riva, Leda Dalprà, Valter Gualandri, Marinella Volontè, Monica Miozzo, Roberta Malgara, Annamaria Fuhrman Conti, Lidia Larizza

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ten leiomyosarcomas (LMS) affecting the same patient over a period of 3 years were cytogenetically studied to detect nonrandom chromosomal changes with a pathogenetic significance. All tumors, likely metastases of a previous LMS presentation, were classified as small, including eight that developed before chemotherapy; the diagnoses were based on standard immunohistochemistry methods for smooth muscle tumors. Scoring of 613 metaphases revealed monosomy of chromosome 22 in six LMS, monosomy of chromosome 19 in three, and deletion of chromosome 19p in all ten. Interphase fluorescence in situ hybridization (FISH) of the 22-alphoid-specific probe allowed loss of the target chromosome to be detected in four tumors at higher frequencies than those detected by cytogenetics. Double-color FISH of the 19p- and 19q-specific YAC performed on one tumor made it possible to distinguish the monosomic and 19p deleted cells, the relative frequencies of which were found to be 10% and 20%, respectively. The deletion breakpoint could be mapped at 19p13 between YAC 957d12 and YAC 947g4. The recurrence of the 19p deletion in a subset of tumor cells from all of the analyzed LMS suggests that this structural aberration is a significant change in the development of leiomyosarcomas. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)102-108
Number of pages7
JournalCancer Genetics and Cytogenetics
Volume119
Issue number2
DOIs
Publication statusPublished - Jun 2000

Fingerprint

Leiomyosarcoma
Monosomy
Fluorescence In Situ Hybridization
Neoplasms
Smooth Muscle Tumor
Chromosomes, Human, Pair 19
Chromosomes, Human, Pair 22
Chromosome Deletion
Interphase
Metaphase
Cytogenetics
Color
Chromosomes
Immunohistochemistry
Neoplasm Metastasis
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

19p Deletion in recurring leiomyosarcoma lesions from the same patient. / Riva, Paola; Dalprà, Leda; Gualandri, Valter; Volontè, Marinella; Miozzo, Monica; Malgara, Roberta; Conti, Annamaria Fuhrman; Larizza, Lidia.

In: Cancer Genetics and Cytogenetics, Vol. 119, No. 2, 06.2000, p. 102-108.

Research output: Contribution to journalArticle

Riva, Paola ; Dalprà, Leda ; Gualandri, Valter ; Volontè, Marinella ; Miozzo, Monica ; Malgara, Roberta ; Conti, Annamaria Fuhrman ; Larizza, Lidia. / 19p Deletion in recurring leiomyosarcoma lesions from the same patient. In: Cancer Genetics and Cytogenetics. 2000 ; Vol. 119, No. 2. pp. 102-108.
@article{e00de137be054594b6450da678bd23d5,
title = "19p Deletion in recurring leiomyosarcoma lesions from the same patient",
abstract = "Ten leiomyosarcomas (LMS) affecting the same patient over a period of 3 years were cytogenetically studied to detect nonrandom chromosomal changes with a pathogenetic significance. All tumors, likely metastases of a previous LMS presentation, were classified as small, including eight that developed before chemotherapy; the diagnoses were based on standard immunohistochemistry methods for smooth muscle tumors. Scoring of 613 metaphases revealed monosomy of chromosome 22 in six LMS, monosomy of chromosome 19 in three, and deletion of chromosome 19p in all ten. Interphase fluorescence in situ hybridization (FISH) of the 22-alphoid-specific probe allowed loss of the target chromosome to be detected in four tumors at higher frequencies than those detected by cytogenetics. Double-color FISH of the 19p- and 19q-specific YAC performed on one tumor made it possible to distinguish the monosomic and 19p deleted cells, the relative frequencies of which were found to be 10{\%} and 20{\%}, respectively. The deletion breakpoint could be mapped at 19p13 between YAC 957d12 and YAC 947g4. The recurrence of the 19p deletion in a subset of tumor cells from all of the analyzed LMS suggests that this structural aberration is a significant change in the development of leiomyosarcomas. Copyright (C) 2000 Elsevier Science Inc.",
author = "Paola Riva and Leda Dalpr{\`a} and Valter Gualandri and Marinella Volont{\`e} and Monica Miozzo and Roberta Malgara and Conti, {Annamaria Fuhrman} and Lidia Larizza",
year = "2000",
month = "6",
doi = "10.1016/S0165-4608(99)00222-8",
language = "English",
volume = "119",
pages = "102--108",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - 19p Deletion in recurring leiomyosarcoma lesions from the same patient

AU - Riva, Paola

AU - Dalprà, Leda

AU - Gualandri, Valter

AU - Volontè, Marinella

AU - Miozzo, Monica

AU - Malgara, Roberta

AU - Conti, Annamaria Fuhrman

AU - Larizza, Lidia

PY - 2000/6

Y1 - 2000/6

N2 - Ten leiomyosarcomas (LMS) affecting the same patient over a period of 3 years were cytogenetically studied to detect nonrandom chromosomal changes with a pathogenetic significance. All tumors, likely metastases of a previous LMS presentation, were classified as small, including eight that developed before chemotherapy; the diagnoses were based on standard immunohistochemistry methods for smooth muscle tumors. Scoring of 613 metaphases revealed monosomy of chromosome 22 in six LMS, monosomy of chromosome 19 in three, and deletion of chromosome 19p in all ten. Interphase fluorescence in situ hybridization (FISH) of the 22-alphoid-specific probe allowed loss of the target chromosome to be detected in four tumors at higher frequencies than those detected by cytogenetics. Double-color FISH of the 19p- and 19q-specific YAC performed on one tumor made it possible to distinguish the monosomic and 19p deleted cells, the relative frequencies of which were found to be 10% and 20%, respectively. The deletion breakpoint could be mapped at 19p13 between YAC 957d12 and YAC 947g4. The recurrence of the 19p deletion in a subset of tumor cells from all of the analyzed LMS suggests that this structural aberration is a significant change in the development of leiomyosarcomas. Copyright (C) 2000 Elsevier Science Inc.

AB - Ten leiomyosarcomas (LMS) affecting the same patient over a period of 3 years were cytogenetically studied to detect nonrandom chromosomal changes with a pathogenetic significance. All tumors, likely metastases of a previous LMS presentation, were classified as small, including eight that developed before chemotherapy; the diagnoses were based on standard immunohistochemistry methods for smooth muscle tumors. Scoring of 613 metaphases revealed monosomy of chromosome 22 in six LMS, monosomy of chromosome 19 in three, and deletion of chromosome 19p in all ten. Interphase fluorescence in situ hybridization (FISH) of the 22-alphoid-specific probe allowed loss of the target chromosome to be detected in four tumors at higher frequencies than those detected by cytogenetics. Double-color FISH of the 19p- and 19q-specific YAC performed on one tumor made it possible to distinguish the monosomic and 19p deleted cells, the relative frequencies of which were found to be 10% and 20%, respectively. The deletion breakpoint could be mapped at 19p13 between YAC 957d12 and YAC 947g4. The recurrence of the 19p deletion in a subset of tumor cells from all of the analyzed LMS suggests that this structural aberration is a significant change in the development of leiomyosarcomas. Copyright (C) 2000 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034080606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034080606&partnerID=8YFLogxK

U2 - 10.1016/S0165-4608(99)00222-8

DO - 10.1016/S0165-4608(99)00222-8

M3 - Article

C2 - 10867143

AN - SCOPUS:0034080606

VL - 119

SP - 102

EP - 108

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 2

ER -